George Perry to alpha-Synuclein
This is a "connection" page, showing publications George Perry has written about alpha-Synuclein.
Connection Strength
1.416
-
Perry G, Zhu X, Babar AK, Siedlak SL, Yang Q, Ito G, Iwatsubo T, Smith MA, Chen SG. Leucine-rich repeat kinase 2 colocalizes with alpha-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener Dis. 2008; 5(3-4):222-4.
Score: 0.274
-
Elbatrawy AA, Ademoye TA, Alnakhala H, Tripathi A, Plascencia-Villa G, Zhu X, Perry G, Dettmer U, Fortin JS. Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against a-synuclein and 2N4R tau. Bioorg Med Chem. 2024 Dec 15; 116:117990.
Score: 0.217
-
Ganegamage SK, Ademoye TA, Patel H, Alnakhala H, Tripathi A, Nguyen CCD, Pham K, Plascencia-Villa G, Zhu X, Perry G, Tian S, Dettmer U, Lasagna-Reeves C, Fortin JS. Evaluation of Alpha-Synuclein and Tau Antiaggregation Activity of Urea and Thiourea-Based Small Molecules for Neurodegenerative Disease Therapeutics. ACS Chem Neurosci. 2024 11 06; 15(21):3915-3931.
Score: 0.217
-
Kelley AR, Colley ME, Perry G, Bach SBH. Incubation with Cu(II) and Zn(II) salts enhances MALDI-TOF mass spectra of amyloid-beta and a-synuclein toward in vivo analysis. J Mass Spectrom. 2018 Feb; 53(2):162-171.
Score: 0.136
-
Vasquez V, Mitra J, Perry G, Rao KS, Hegde ML. An Inducible Alpha-Synuclein Expressing Neuronal Cell Line Model for Parkinson's Disease1. J Alzheimers Dis. 2018; 66(2):453-460.
Score: 0.135
-
Nunomura A, Zhu X, Perry G. Modulation of Parkinson's Disease Associated Protein Rescues Alzheimer's Disease Degeneration. J Alzheimers Dis. 2017; 55(1):73-75.
Score: 0.126
-
Lee HG, Zhu X, Takeda A, Perry G, Smith MA. Emerging evidence for the neuroprotective role of alpha-synuclein. Exp Neurol. 2006 Jul; 200(1):1-7.
Score: 0.061
-
Hasegawa T, Matsuzaki-Kobayashi M, Takeda A, Sugeno N, Kikuchi A, Furukawa K, Perry G, Smith MA, Itoyama Y. Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease. FEBS Lett. 2006 Apr 03; 580(8):2147-52.
Score: 0.060
-
Sayre LM, Moreira PI, Smith MA, Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanita. 2005; 41(2):143-64.
Score: 0.055
-
Ramirez E, Ganegamage SK, Min S, Patel H, Ogunware A, Plascencia-Villa G, Alnakhala H, Shimanaka K, Tripathi A, Wang KW, Zhu X, Rochet JC, Kuo MH, Counts SE, Perry G, Dettmer U, Lasagna-Reeves CA, Fortin JS. Evaluation of N- and O-Linked Indole Triazines for a Dual Effect on a-Synuclein and Tau Aggregation. ACS Chem Neurosci. 2023 11 01; 14(21):3913-3927.
Score: 0.050
-
Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, Litvan I, Mata IF, Zabetian CP, Brundin P, Fernandez HH, Standaert DG, Kauffman MA, Schwarzschild MA, Sardi SP, Sherer T, Perry G, Leverenz JB. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 2019 02 12; 92(7):329-337.
Score: 0.036
-
Castellani RJ, Nugent SL, Morrison AL, Zhu X, Lee HG, Harris PL, Bajic V, Sharma HS, Chen SG, Oettgen P, Perry G, Smith MA. CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease. J Neural Transm (Vienna). 2011 Jan; 118(1):23-6.
Score: 0.021
-
Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG. LRRK2 protein is a component of Lewy bodies. Ann Neurol. 2006 Nov; 60(5):617-618.
Score: 0.016
-
Hasegawa T, Matsuzaki M, Takeda A, Kikuchi A, Akita H, Perry G, Smith MA, Itoyama Y. Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res. 2004 Jul 02; 1013(1):51-9.
Score: 0.013